TherapeuticsMD, Inc. (NASDAQ:TXMD) Short Interest Update

TherapeuticsMD, Inc. (NASDAQ:TXMD) was the recipient of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 12,000 shares, a drop of 43.7% from the December 15th total of 21,300 shares. Based on an average trading volume of 275,000 shares, the short-interest ratio is presently 0.0 days. Currently, 0.1% of the company’s stock are sold short.

TherapeuticsMD Trading Up 0.9 %

NASDAQ TXMD traded up $0.01 on Thursday, reaching $1.12. The company had a trading volume of 10,232 shares, compared to its average volume of 1,638,088. The company’s fifty day moving average is $1.25 and its 200 day moving average is $1.54. TherapeuticsMD has a 52-week low of $0.70 and a 52-week high of $2.75.

Institutional Trading of TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP boosted its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the period. Clearline Capital LP owned about 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. Institutional investors and hedge funds own 30.74% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on TherapeuticsMD in a research report on Tuesday. They set a “hold” rating on the stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.